PO Box 11183
Ellerslie
Auckland 1542
New Zealand

6 April 2023

Dear Healthcare Professional,

Product Packaging Change Notification – LOGEM® (lamotrigine)

Viatris Ltd has updated the packaging artwork for LOGEM® 25 mg, 50 mg, 100 mg chewable/dispersible tablets in the New Zealand market.

Please note there have been **no changes to the products' formulation**, Pharma Code or the Viatris EAN code.

Summary of the Changes

There has been packaging changes coinciding with rebranding from Mylan to Viatris as shown below:

Old Packaging	New Packaging
	
	
	

The prescribing and provision of patient counselling by healthcare professionals should continue in accordance with the New Zealand Data Sheet for LOGEM (Viatris branding & Sponsor Details updated) that may be accessed at www.medsafe.govt.nz

Reporting Adverse Events

Reporting suspected adverse reactions has an important role in monitoring the benefit/risk balance of medicines. Please report any suspected adverse events via email to Viatris Ltd at medinfo_anz@viatris.com . Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) at https://nzphvc.otago.ac.nz . When reporting, please provide as much information as possible, including information about medical history, any concomitant medication, onset and treatment dates.

If you have any questions related to this product, please contact Medical Information Viatris Medical Information by emailing medinfo_anz@viatris.com or telephone on 0800 737 271.

Yours sincerely,

Manar Al-Murrani,

Medical Affairs Specialist

Chris Honeybun

Quality Manager